July 27, 2018 Drug Utilization Review Board
»
1. Call to order
1. Call to order
»
2. Approval of minutes from April 27, 2018 (vote required)
2. Approval of minutes from April 27, 2018 (vote required)
»
3. Elect chair (vote required)
3. Elect chair (vote required)
»
4. Bylaws revision (vote required)
4. Bylaws revision (vote required)
»
5. Old business: Report on Health and Human Services Commission decisions on acceptance of the Drug Utilization Review (DUR) Board recommendations from the April 27, 2018, meeting
5. Old business: Report on Health and Human Services Commission decisions on acceptance of the Drug Utilization Review (DUR) Board recommendations from the April 27, 2018, meeting
»
6. New business:
Public comment on drug classes and therapeutic and clinical drug reviews to be reviewed for the Medicaid Preferred Drug List (PDL): » - a. Alzheimer’s agents b. Antihistamines, minimally sedating c. Antihypertensives, sympatholytics d. Calcium channel blockers e. Cephalosporins and related antibiotics f. Fluoroquinolones, oral g. Glucocorticoids, oral h. Immunosuppressives, oral i. Iron, oral j. Leukotriene Modifiers k. Nonsteroidal anti-inflammatory drugs (NSAIDs) l. Ophthalmic antibiotics m. Ophthalmic antibiotic-steroid combinations n. Ophthalmic for allergic conjunctivitis o. Ophthalmic anti-inflammatories p. Ophthalmic, glaucoma agents q. Otic antibiotics r. Otic anti-infectives and anesthetics s. Prenatal vitamins t. Skeletal muscle relaxants u. Steroids, topical high v. Steroids, topical low w. Steroids, topical medium x. Steroids, topical very high y. Ulcerative colitis agents a. Anticoagulants / Eliquis Dose Pack b. Antiemetic / Antivertigo Agents / Bonjesta c. Chronic Obstructive Pulmonary Disease (COPD) / Lonhala Magnair d. Hypoglycemics, incretin mimetics/enhancers / Steglujan e. Hypoglycemics, insulin and related agents / Toujeo Max Solostar Pen f. Hypoglycemics, SGLT2 / Segluromet g. Lipotropics, statins / Zypitamag h. Progestational agents / Makena Auto Injector
6. New business: Public comment on drug classes and therapeutic and clinical drug reviews to be reviewed for the Medicaid Preferred Drug List (PDL): »
a. Alzheimer’s agents b. Antihistamines, minimally sedating
c. Antihypertensives, sympatholytics
d. Calcium channel blockers
e. Cephalosporins and related antibiotics
f. Fluoroquinolones, oral
g. Glucocorticoids, oral
h. Immunosuppressives, oral
i. Iron, oral
j. Leukotriene Modifiers
k. Nonsteroidal anti-inflammatory drugs (NSAIDs)
l. Ophthalmic antibiotics
m. Ophthalmic antibiotic-steroid combinations
n. Ophthalmic for allergic conjunctivitis
o. Ophthalmic anti-inflammatories
p. Ophthalmic, glaucoma agents
q. Otic antibiotics
r. Otic anti-infectives and anesthetics
s. Prenatal vitamins
t. Skeletal muscle relaxants
u. Steroids, topical high
v. Steroids, topical low
w. Steroids, topical medium
x. Steroids, topical very high
y. Ulcerative colitis agents
a. Anticoagulants / Eliquis Dose Pack
b. Antiemetic / Antivertigo Agents / Bonjesta
c. Chronic Obstructive Pulmonary Disease (COPD) / Lonhala Magnair
d. Hypoglycemics, incretin mimetics/enhancers / Steglujan
e. Hypoglycemics, insulin and related agents / Toujeo Max Solostar Pen
f. Hypoglycemics, SGLT2 / Segluromet
g. Lipotropics, statins / Zypitamag
h. Progestational agents / Makena Auto Injector
»
Items 7 & 8 » - 7. Executive work session
Pursuant to Texas Government Code, Section 531.071, and in accordance with Texas Administrative Code, Title 1, Part 15, Subchapter F, Section 354.1941(c)(2), the DUR Board may meet in executive session on one or more items listed under new business as permitted by the Texas Open Meetings Act. 8. Lunch
Items 7 & 8 »
7. Executive work sessionPursuant to Texas Government Code, Section 531.071, and in accordance with Texas Administrative Code, Title 1, Part 15, Subchapter F, Section 354.1941(c)(2), the DUR Board may meet in executive session on one or more items listed under new business as permitted by the Texas Open Meetings Act.
8. Lunch
»
9. Announcements of drugs recommended for the Medicaid PDL (vote required)
9. Announcements of drugs recommended for the Medicaid PDL (vote required)
»
10. Retrospective DUR: Larry Dent, Pharm. D., BCPS, Conduent, LLC » - a. Report on recent retrospective DUR intervention: i. Hypertension management ii. Major depressive disorder management b. Report on recent retrospective DUR intervention outcomes: i. Metabolic syndrome ii. Second-generation antipsychotics in youth c. Retrospective DUR proposals: (vote required) i. Opioid prescribing ii. Second-generation antipsychotics in youth
10. Retrospective DUR: Larry Dent, Pharm. D., BCPS, Conduent, LLC »
a. Report on recent retrospective DUR intervention: i. Hypertension management
ii. Major depressive disorder management
b. Report on recent retrospective DUR intervention outcomes:
i. Metabolic syndrome
ii. Second-generation antipsychotics in youth
c. Retrospective DUR proposals: (vote required)
i. Opioid prescribing
ii. Second-generation antipsychotics in youth
»
11. Prospective prior authorization proposals (clinical edits): Christina Faulkner, Pharm. D., Health Information Designs, LLC (vote required) » - a. Carisoprodol Containing Agents - revision b. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Combination Agents - new
11. Prospective prior authorization proposals (clinical edits): Christina Faulkner, Pharm. D., Health Information Designs, LLC (vote required) »
a. Carisoprodol Containing Agents - revision b. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Combination Agents - new
»
Items 12 - 14 » - 12. Retrospective drug use, criteria for outpatient use in Vendor Drug Program: Jennifer Seltzer, Pharm. D., University of Texas at Austin College of Pharmacy (vote required) a. Hepatitis C direct-acting antivirals b. Immune Globulins c. Oral/Rectal NSAIDs d. Non-sedating antihistamines e. Oral Fluoroquinolones f. Rifaximin (Xifaxan®) g. Sedative / Hypnotics h. Skeletal muscle relaxants 13. Adjourn 14. Next meeting date: October 26, 2018
Items 12 - 14 »
12. Retrospective drug use, criteria for outpatient use in Vendor Drug Program: Jennifer Seltzer, Pharm. D., University of Texas at Austin College of Pharmacy (vote required) a. Hepatitis C direct-acting antivirals
b. Immune Globulins
c. Oral/Rectal NSAIDs
d. Non-sedating antihistamines
e. Oral Fluoroquinolones
f. Rifaximin (Xifaxan®)
g. Sedative / Hypnotics
h. Skeletal muscle relaxants
13. Adjourn
14. Next meeting date: October 26, 2018
